


**Prostate Cancer Moderate Hypofractionation Interim Recommendations**  
**Consensus Group Statement June 2023**


The Radiation Oncology section of the National Clinical Guideline No. 8 Diagnosis, Staging and Treatment of Patients with Prostate Cancer is under review to be updated.

The capacity subgroup of the National Radiation Oncology Working Group endorse the recommendations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer pertaining to moderate hypofractionation regimens (only) as interim guidance (Table 1- PROS-G 4 OF 7). The NCCN recommendations for moderate fractionation in low to high-risk patients are based on evidence from randomised phase III trials, however in node positive patients there is a paucity of evidence available on the optimum fractionation schedules. It should be noted that this is a consensus of the capacity subgroup of the National Radiation Oncology Working Group and has not been developed as an NCCP evidence based guideline. This endorsement does not cover any other section of the NCCN Prostate cancer guideline.

Please note, the recommendations are for guidance purposes only. The appropriate application and correct use of the recommendations is the responsibility of each health professional. The capacity subgroup of the National Radiation Oncology Working Group expectation is that health professionals will use clinical knowledge and judgment in applying the principles and recommendations. These recommendations may not be appropriate in all circumstances and it may be necessary to deviate from these recommendations. Clinical judgment in such a decision must be clearly documented. Care options should be discussed with the patient, his/her significant other(s), and the multidisciplinary team on a case-by-case basis as necessary. The NCCP accepts no liability nor shall it be liable, whether arising directly or indirectly, to the user or any other third party for any claims, loss or damage resulting from any use of the recommendations.

Click on the following link to NCCN Clinical Practice Guidelines in Oncology.  
[https://www.nccn.org/guidelines/category\\_1](https://www.nccn.org/guidelines/category_1)

Signed:   
\_\_\_\_\_  
Professor Clare Faul  
Network Director SLRON  
Clinical advisor Radiation Oncology, NCCP

Signed:   
\_\_\_\_\_  
Professor Risteárd Ó Laoide  
National Director  
National Cancer Control Programme